Scinai Immunotherapeutics
SCNI
12 hedge funds and large institutions have $2.98M invested in Scinai Immunotherapeutics in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.
15% more capital invested
Capital invested by funds: $2.58M → $2.98M (+$399K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less funds holding
Funds holding: 15 → 12 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$57K |
| 2 |
Renaissance Technologies
New York
|
-$55K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23.3K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$18K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $2.4M | – | – | – |
|
|
BHB
2
Bank Hapoalim BM
Tel Aviv,
Israel
| $180K | – | – | – |
|
|
VIA
3
Vantage Investment Advisors
State College,
Pennsylvania
| $140K | – | – | – |
|
4
HighTower Advisors
Chicago,
Illinois
| $112K | – | – | – |
|
|
PVH
5
Psagot Value Holdings
Tel Aviv,
Israel
| $73K | – | – | – |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $44K | -$23.3K | -36 | -35% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $8K | -$5.18K | -8 | -38% |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $6K | – | – | – |
|
11
Morgan Stanley
New York
| $3K | – | – | – |
|
|
HIIFS
12
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | -$57K | -105 | Closed |
|
|
13
Renaissance Technologies
New York
| – | -$55K | -102 | Closed |
|
|
DCM
14
DAFNA Capital Management
Los Angeles,
California
| – | -$18K | -34 | Closed |
|
SCNI Hedge Fund Activity: Q2 2018 in Review
12 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2018, worth a combined $2.98M — up 15% from $2.58M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $57K sold.
- 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2018, down from 15 in Q1 2018.
- Funds reported $2.98M of Scinai Immunotherapeutics stock for Q2 2018, up 15% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q2 2018 and 3 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics seller in Q2 2018 was Harel Insurance Investments & Financial Services, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2018.